← Leaderboards
Joan E. Durbin
Research Inst Nationwide Children'S Hosp
$11,877,495
Attributed
$15,503,778
Total exposure
6
Grants
4
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $2.3M · FY2005–17$2.5M$1.9M$1.3M$625K$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$15,503,778 · 6
By mechanism
R01$13,686,803 · 4
U01$1,636,975 · 1
R21$180,000 · 1
Top collaborators
- Sergei V Kotenko6 shared
- Lauren O Bakaletz3 shared
Most similar at Research Inst Nationwide Children'S Hosp
Same institution · by research overlap
- Lauren O Bakaletz$21,163,452
- Mark E. Peeples$12,658,136
Others in their field
Top investigators on “Virus Diseases”
- Barton F Haynes · Duke University$305,832,186
- Glenda E Gray · Wits Health Consortium (Pty), Ltd$274,342,142
- Lawrence Corey · Fred Hutchinson Cancer Center$271,990,515
- Richard Webby · St. Jude Children'S Research Hospital$264,105,723
- David Heimbrook · Leidos Biomedical Research, Inc.$262,417,885
- Margaret Juliana McElrath · Fred Hutchinson Cancer Center$252,117,999
Research focus
Virus DiseasesPathogenRespiratory Syncytial VirusInfectionImmunityLifeVirusAnimal ModelPreventImmuneResponseCytokineBaseProductionAntiviral AgentsIn VivoCellsViralLymphocyteInterferonsLaboratoriesGenesImmune SystemSafety
Grant awards (27)
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$1,190,331
R01 · FY2017 · AI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$1,185,932
R01 · FY2016 · AI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$1,185,932
R01 · FY2015 · AI
SUPPLEMENT TO: A Novel approach to RSV vaccination$603,068
R01 · FY2015 · AI · contact PI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$1,185,617
R01 · FY2014 · AI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$1,036,895
R01 · FY2013 · AI
SUPPLEMENT TO: A Novel approach to RSV vaccination$525,527
R01 · FY2013 · AI · contact PI
SUPPLEMENT TO: A Novel approach to RSV vaccination$429,293
R01 · FY2013 · AI · contact PI
A Novel Approach to RSV Vaccination$204,772
R01 · FY2013 · AI · contact PI
Development of IFN-lambda3 for the Prevention and Treatment of Virus Infection$150,180
R01 · FY2013 · AI
A Novel Approach to RSV Vaccination$601,453
R01 · FY2012 · AI · contact PI
A Novel Approach to RSV Vaccination$600,131
R01 · FY2011 · AI · contact PI
The Role of Type III Interferon in Innate Immunity to Respiratory Virus Infection$809,880
U01 · FY2010 · AI · contact PI
A Novel Approach to RSV Vaccination$698,083
R01 · FY2010 · AI · contact PI
RSV Upper Airway Infection and Otitis Media$438,448
R01 · FY2010 · DC · contact PI
The Role of Type III Interferon in Innate Immunity to Respiratory Virus Infection$827,095
U01 · FY2009 · AI · contact PI
RSV Upper Airway Infection and Otitis Media$450,553
R01 · FY2009 · DC · contact PI
RSV Upper Airway Infection and Otitis Media$428,678
R01 · FY2008 · DC · contact PI
Visualizing Interferon-beta Induction In Vivo$180,000
R21 · FY2008 · AI · contact PI
RSV Upper Airway Infection & Otitis Media$453,034
R01 · FY2006 · DC · contact PI
RSV Upper Airway Infection &Otitis Media$450,421
R01 · FY2005 · DC
RSV Upper Airway Infection &Otitis Media$437,306
R01 · FY2004 · DC
INTERFERON-ALPHA/BETA IN RESPIRATORY VIRUS PATHOGENESIS$343,125
R01 · FY2004 · AI
INTERFERON-ALPHA/BETA IN RESPIRATORY VIRUS PATHOGENESIS$371,836
R01 · FY2003 · AI
INTERFERON-ALPHA/BETA IN RESPIRATORY VIRUS PATHOGENESIS$343,125
R01 · FY2002 · AI
INTERFERON-ALPHA/BETA IN RESPIRATORY VIRUS PATHOGENESIS$49,000
R01 · FY2002 · AI
INTERFERON-ALPHA/BETA IN RESPIRATORY VIRUS PATHOGENESIS$324,063
R01 · FY2001 · AI